Octreotide-induced	octreotide-induced	O	O
hypoxemia	hypoxemia	O	O
and	and	O	O
pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
in	in	O	O
premature	premature	O	O
neonates	neonates	O	O
.	.	O	O

The	the	O	O
authors	authors	O	O
report	report	O	O
2	2	O	O
cases	cases	O	O
of	of	O	O
premature	premature	O	O
neonates	neonates	O	O
who	who	O	O
had	had	O	O
enterocutaneous	enterocutaneous	O	B_disease
fistula	fistula	O	S_disease
complicating	complicating	O	O
necrotizing	necrotizing	O	B_disease
enterocolitis	enterocolitis	O	S_disease
.	.	O	O

Pulmonary	pulmonary	O	B_disease
hypertension	hypertension	O	S_disease
developed	developed	O	O
after	after	O	O
administration	administration	O	O
of	of	O	O
a	a	O	O
somatostatin	somatostatin	S_chemicals	O
analogue	analogue	O	O
,	,	O	O
octreotide	octreotide	S_chemicals	O
,	,	O	O
to	to	O	O
enhance	enhance	O	O
resolution	resolution	O	O
of	of	O	O
the	the	O	O
fistula	fistula	O	S_disease
.	.	O	O

The	the	O	O
authors	authors	O	O
discuss	discuss	O	O
the	the	O	O
mechanism	mechanism	O	O
of	of	O	O
the	the	O	O
occurrence	occurrence	O	O
of	of	O	O
this	this	O	O
complication	complication	O	O
and	and	O	O
recommend	recommend	O	O
caution	caution	O	O
of	of	O	O
its	its	O	O
use	use	O	O
in	in	O	O
high-risk	high-risk	O	O
premature	premature	O	O
neonates	neonates	O	O
.	.	O	O

